Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Effect of perioperative aspirin use on hemorrhagic complications in elective craniotomy for brain tumors: results of a single-center, retrospective cohort study.

Hanalioglu S, Sahin B, Sahin OS, Kozan A, Ucer M, Cikla U, Goodman SL, Baskaya MK.

J Neurosurg. 2019 Apr 5:1-10. doi: 10.3171/2018.12.JNS182483. [Epub ahead of print]

PMID:
30952120
2.

The 3rd Antibody Validation meeting: Bath UK 20-21 st September 2018.

Goodman SL.

F1000Res. 2018 Dec 31;7:1989. doi: 10.12688/f1000research.17645.1. eCollection 2018.

3.

The path to VICTORy - a beginner's guide to success using commercial research antibodies.

Goodman SL.

J Cell Sci. 2018 May 15;131(10). pii: jcs216416. doi: 10.1242/jcs.216416. Review.

4.

The antibody horror show: an introductory guide for the perplexed.

Goodman SL.

N Biotechnol. 2018 Oct 25;45:9-13. doi: 10.1016/j.nbt.2018.01.006. Epub 2018 Feb 3.

PMID:
29355666
5.

Integrins as Therapeutic Targets: Successes and Cancers.

Raab-Westphal S, Marshall JF, Goodman SL.

Cancers (Basel). 2017 Aug 23;9(9). pii: E110. doi: 10.3390/cancers9090110. Review.

6.

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment.

Blancett CD, Monninger MK, Nguessan CA, Kuehl KA, Rossi CA, Olschner SP, Williams PL, Goodman SL, Sun MG.

J Vis Exp. 2017 Jul 19;(125). doi: 10.3791/56122.

7.

Preparation of viral samples within biocontainment for ultrastructural analysis: Utilization of an innovative processing capsule for negative staining.

Monninger MK, Nguessan CA, Blancett CD, Kuehl KA, Rossi CA, Olschner SP, Williams PL, Goodman SL, Sun MG.

J Virol Methods. 2016 Dec;238:70-76. doi: 10.1016/j.jviromet.2016.10.005. Epub 2016 Oct 14.

8.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman SL, Hegi ME, Picard M, Moch H, Straub J, Stupp R.

Oncotarget. 2016 Mar 22;7(12):15018-32. doi: 10.18632/oncotarget.7588.

9.

Electronic Documentation Templates Support ICD-10-CM/PCS Implementation (Updated).

Buttner P, Goodman SL, Love TR, McLeod M, Stearns M.

J AHIMA. 2015 Jun;86(6):56-62. No abstract available.

PMID:
26489232
10.

Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer.

Böger C, Warneke VS, Behrens HM, Kalthoff H, Goodman SL, Becker T, Röcken C.

Gastric Cancer. 2015 Oct;18(4):784-95. doi: 10.1007/s10120-014-0435-2. Epub 2014 Oct 15.

11.

αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M, Goodman SL, Birner P, Preusser M.

Clin Exp Metastasis. 2014 Oct;31(7):841-51. doi: 10.1007/s10585-014-9675-0. Epub 2014 Aug 24.

PMID:
25150423
12.

Atomic basis for the species-specific inhibition of αV integrins by monoclonal antibody 17E6 is revealed by the crystal structure of αVβ3 ectodomain-17E6 Fab complex.

Mahalingam B, Van Agthoven JF, Xiong JP, Alonso JL, Adair BD, Rui X, Anand S, Mehrbod M, Mofrad MR, Burger C, Goodman SL, Arnaout MA.

J Biol Chem. 2014 May 16;289(20):13801-9. doi: 10.1074/jbc.M113.546929. Epub 2014 Apr 1.

13.

Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin.

Van Agthoven JF, Xiong JP, Alonso JL, Rui X, Adair BD, Goodman SL, Arnaout MA.

Nat Struct Mol Biol. 2014 Apr;21(4):383-8. doi: 10.1038/nsmb.2797. Epub 2014 Mar 23.

14.

Comparing the expression of integrins αvβ3, αvβ5, αvβ6, αvβ8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors.

Schittenhelm J, Klein A, Tatagiba MS, Meyermann R, Fend F, Goodman SL, Sipos B.

Int J Clin Exp Pathol. 2013 Nov 15;6(12):2719-32. eCollection 2013.

15.

Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression.

Böger C, Kalthoff H, Goodman SL, Behrens HM, Röcken C.

Virchows Arch. 2014 Jan;464(1):69-78. doi: 10.1007/s00428-013-1506-1. Epub 2013 Nov 26.

PMID:
24276405
16.

Invasion patterns in brain metastases of solid cancers.

Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M.

Neuro Oncol. 2013 Dec;15(12):1664-72. doi: 10.1093/neuonc/not112. Epub 2013 Sep 30.

17.

αv-Integrin isoform expression in primary human tumors and brain metastases.

Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H.

Int J Cancer. 2013 Nov 15;133(10):2362-71. doi: 10.1002/ijc.28267. Epub 2013 Jun 10.

18.

Validation and comparison of anti-αvβ3 and anti-αvβ5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities.

Böger C, Kalthoff H, Goodman SL, Röcken C.

Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):553-60. doi: 10.1097/PAI.0b013e318284a03a.

PMID:
23455183
19.

Longitudinal expression analysis of αv integrins in human gliomas reveals upregulation of integrin αvβ3 as a negative prognostic factor.

Schittenhelm J, Schwab EI, Sperveslage J, Tatagiba M, Meyermann R, Fend F, Goodman SL, Sipos B.

J Neuropathol Exp Neurol. 2013 Mar;72(3):194-210. doi: 10.1097/NEN.0b013e3182851019.

PMID:
23399898
20.

Integrin control of the transforming growth factor-β pathway in glioblastoma.

Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M.

Brain. 2013 Feb;136(Pt 2):564-76. doi: 10.1093/brain/aws351. Epub 2013 Jan 31.

21.
22.

The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.

Ten Hagen TL, Seynhaeve AL, de Wiel-Ambagtsheer Ga, de Bruijn EA, van Tiel ST, Ruegg C, Meyring M, Grell M, Goodman SL, Eggermont AM.

Int J Cancer. 2013 Jun 1;132(11):2694-704. doi: 10.1002/ijc.27940. Epub 2012 Dec 5.

23.

Integrins as therapeutic targets.

Goodman SL, Picard M.

Trends Pharmacol Sci. 2012 Jul;33(7):405-12. doi: 10.1016/j.tips.2012.04.002. Epub 2012 May 25. Review.

PMID:
22633092
24.
25.

Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.

Bäuerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W.

Int J Cancer. 2011 May 15;128(10):2453-62. doi: 10.1002/ijc.25563.

26.

Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.

Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sägesser H, Niedobitek G, Goodman SL, Schuppan D.

Hepatology. 2009 Nov;50(5):1501-11. doi: 10.1002/hep.23144.

27.

Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment.

Xiong JP, Mahalingham B, Alonso JL, Borrelli LA, Rui X, Anand S, Hyman BT, Rysiok T, Müller-Pompalla D, Goodman SL, Arnaout MA.

J Cell Biol. 2009 Aug 24;186(4):589-600. doi: 10.1083/jcb.200905085.

28.

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.

Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL.

Int J Cancer. 2009 Jun 1;124(11):2719-27. doi: 10.1002/ijc.24240.

29.

Circulating and imaging markers for angiogenesis.

Pathak AP, Hochfeld WE, Goodman SL, Pepper MS.

Angiogenesis. 2008;11(4):321-35. doi: 10.1007/s10456-008-9119-z. Epub 2008 Oct 17. Review.

PMID:
18925424
30.

CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma.

Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M, Rüegg C.

Cancer Res. 2008 Sep 15;68(18):7323-31. doi: 10.1158/0008-5472.CAN-08-0841.

31.

Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression.

Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D.

Gastroenterology. 2008 Aug;135(2):660-70. doi: 10.1053/j.gastro.2008.04.009. Epub 2008 Apr 16.

32.

Structure and mechanics of integrin-based cell adhesion.

Arnaout MA, Goodman SL, Xiong JP.

Curr Opin Cell Biol. 2007 Oct;19(5):495-507. Epub 2007 Oct 24. Review.

33.

Purification, analysis, and crystal structure of integrins.

Xiong JP, Goodman SL, Arnaout MA.

Methods Enzymol. 2007;426:307-36. Review.

PMID:
17697890
34.

Platelet responses to silicon-alloyed pyrolytic carbons.

Goodman SL, Scranton VL, Brendzel AM.

J Biomed Mater Res A. 2007 Oct;83(1):64-9.

PMID:
17380499
35.

Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappaB activation and endothelial cell survival.

Bieler G, Hasmim M, Monnier Y, Imaizumi N, Ameyar M, Bamat J, Ponsonnet L, Chouaib S, Grell M, Goodman SL, Lejeune F, Rüegg C.

Oncogene. 2007 Aug 23;26(39):5722-32. Epub 2007 Mar 19.

PMID:
17369858
36.

Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro.

Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D.

J Hepatol. 2007 May;46(5):878-87. Epub 2006 Dec 12.

PMID:
17258347
37.

Piltdown wasn't cricket but does the hobbit ring true?

Goodman SL.

Nature. 2006 Sep 28;443(7110):394. No abstract available.

PMID:
17006491
38.

Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical.

Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, Wiesner M, Murphy G, Overall CM, Goodman SL, Pepper MS.

Cancer Res. 2005 Oct 15;65(20):9377-87.

39.

Titanium implant materials with improved biocompatibility through coating with phosphonate-anchored cyclic RGD peptides.

Auernheimer J, Zukowski D, Dahmen C, Kantlehner M, Enderle A, Goodman SL, Kessler H.

Chembiochem. 2005 Nov;6(11):2034-40.

PMID:
16206226
40.
41.

Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin.

Adair BD, Xiong JP, Maddock C, Goodman SL, Arnaout MA, Yeager M.

J Cell Biol. 2005 Mar 28;168(7):1109-18.

42.

Improving implant materials by coating with nonpeptidic, highly specific integrin ligands.

Dahmen C, Auernheimer J, Meyer A, Enderle A, Goodman SL, Kessler H.

Angew Chem Int Ed Engl. 2004 Dec 10;43(48):6649-52. No abstract available.

PMID:
15593169
43.

Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro.

Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, Goodman SL, Kosmahl M, Klöppel G.

Histopathology. 2004 Sep;45(3):226-36.

PMID:
15330800
44.

A novel adaptation of the integrin PSI domain revealed from its crystal structure.

Xiong JP, Stehle T, Goodman SL, Arnaout MA.

J Biol Chem. 2004 Sep 24;279(39):40252-4. Epub 2004 Aug 6.

45.

RGD-mutants of B-lymphotropic polyomavirus capsids specifically bind to alpha(v)beta3 integrin.

Langner J, Neumann B, Goodman SL, Pawlita M.

Arch Virol. 2004 Oct;149(10):1877-96.

PMID:
15290355
46.

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS.

Angiogenesis. 2003;6(2):105-19.

PMID:
14739617
47.

Integrins, cations and ligands: making the connection.

Xiong JP, Stehle T, Goodman SL, Arnaout MA.

J Thromb Haemost. 2003 Jul;1(7):1642-54. Review.

48.
49.

New insights into the structural basis of integrin activation.

Xiong JP, Stehle T, Goodman SL, Arnaout MA.

Blood. 2003 Aug 15;102(4):1155-9. Epub 2003 Apr 24. Review.

50.

Coming to grips with integrin binding to ligands.

Arnaout MA, Goodman SL, Xiong JP.

Curr Opin Cell Biol. 2002 Oct;14(5):641-51. Review.

PMID:
12231361

Supplemental Content

Loading ...
Support Center